Transce3nd’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
Other funds holding NTLA
Transce3nd's NTLA Position: Q3 2026 in Review
Transce3nd opened a new position in Intellia Therapeutics (NTLA) in Q3 2026: 53 shares worth $617. The stake represents ﹤0.01% of the portfolio and ranks #516 among its holdings.
312 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.
- Transce3nd held 53 shares of Intellia Therapeutics worth $617 as of Q3 2026.
- Intellia Therapeutics was a new Transce3nd position in Q3 2026.
- Intellia Therapeutics made up ﹤0.01% of Transce3nd's portfolio in Q3 2026, its #516 holding.
- 312 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.
Based on Transce3nd's 13F filing for Q3 2026, filed 26 Oct 2026.